Aquestive Therapeutics Cash Flow Statement
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.78+0.02 (+0.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aquestive Therapeutics free cash flow
In fiscal 2025, Aquestive Therapeutics generated -$52.4 million of operating cash flow and spent $562,000 on capital expenditures. That left free cash flow of -$53.0 million, a free-cash-flow margin of -119.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Aquestive Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -83.78M | -44.14M | -7.87M | -54.41M | -70.54M | -55.78M | -66.25M | -61.38M | -8.94M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 548.00K | 718.00K | 1.34M | 2.39M | 2.96M | 3.44M | 2.90M | 3.19M | 3.75M |
| Stock-Based Compensation | 7.62M | 7.10M | 2.69M | 4.38M | 6.82M | 6.58M | 7.07M | 29.94M | 0 |
| Change in Working Capital | 9.15M | -8.46M | -2.83M | 33.68M | -886.00K | -7.39M | -11.12M | 8.00M | 8.05M |
| Operating Cash Flow | -52.43M | -35.76M | -6.38M | -9.82M | -32.98M | -45.46M | -60.21M | -12.99M | 5.82M |
| Capital Expenditures | -562.00K | -159.00K | -995.00K | -1.02M | -913.00K | -517.00K | -663.00K | -1.82M | -2.07M |
| Investing Cash Flow | -562.00K | -159.00K | -995.00K | -2.52M | -913.00K | -517.00K | -663.00K | -1.82M | -2.07M |
| Debt Issued | — | 0 | 31.14M | 0 | — | 0 | 70.00M | 0 | 5.00M |
| Debt Repaid | -26.00K | -23.00K | -51.53M | 0 | 0 | -22.50M | -50.00M | 0 | — |
| Financing Cash Flow | 102.62M | 83.59M | 3.97M | 11.59M | 30.11M | 28.46M | 49.60M | 58.03M | 4.41M |
| Net Change in Cash | 49.62M | 47.67M | -3.40M | -751.00K | -3.78M | -17.52M | -11.27M | 43.22M | 8.17M |
| Free Cash Flow | -52.99M | -35.92M | -7.38M | -10.84M | -33.89M | -45.98M | -60.87M | -14.81M | 3.76M |
This table shows 9 annual periods of Aquestive Therapeutics's cash flow statement, from FY 2025 back to FY 2017, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AQST's reporting calendar. What is a cash flow statement?